Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4205.70 +0.8% SILVER 57.78 +1.1% COPPER 6.60 +0.7% OIL 95.97 −2.0% PALLADIUM 1127.25 −0.1% OMI 0.250 +0.0% BUFF 0.810 +3.9% FEO 0.650 +0.0% LIB 0.750 +4.2% NPR 0.630 +1.6% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.540 +3.9% FMR 0.225 +0.0% GSVR 0.352 +3.7% PHNM 0.340 +0.0% SLG 5.50 −3.7% CASA 0.060 +0.0% DRY 0.220 +2.3% SOMA 0.550 −1.8% PWRO 0.025 +0.0% GOLD 4205.70 +0.8% SILVER 57.78 +1.1% COPPER 6.60 +0.7% OIL 95.97 −2.0% PALLADIUM 1127.25 −0.1% OMI 0.250 +0.0% BUFF 0.810 +3.9% FEO 0.650 +0.0% LIB 0.750 +4.2% NPR 0.630 +1.6% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.540 +3.9% FMR 0.225 +0.0% GSVR 0.352 +3.7% PHNM 0.340 +0.0% SLG 5.50 −3.7% CASA 0.060 +0.0% DRY 0.220 +2.3% SOMA 0.550 −1.8% PWRO 0.025 +0.0%
Other Routine +

PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

Sairiyo Therapeutics Advances Hantavirus Pipeline Amidst Dilution and Debt Overhang

By The Northwire Desk — AI Analysis May 13, 2026 · 08:51 PHRX · 0.01 Pharmadrug Inc.
Executive Summary
  • Most Recent Event (May 13, 2026): PharmaDrug's subsidiary, Sairiyo Therapeutics, received approval from an Australian Human Research Ethics Committee to initiate a Phase 1 clinical study of PD-001 for Hantavirus.
  • Preclinical Data: Independent research showed cepharanthine inhibited Hantavirus pseudovirus infection by up to 94% in mouse models at various doses (45mg/kg to 180mg/kg).
  • Drug Candidate: PD-001 is a patented enteric-coated oral formulation of Cepharanthine designed to improve bioavailability compared to generic versions.
  • Intellectual Property: Protected by US Patent US10576077 expiring March 23, 2036.
  • Historical Context (Jan 2026): Completed acquisition of initial 19.9% interest in Canurta Inc., issued $445,686 secured convertible debentures to restructure debt, and Atlas365 acquired ~19.4% stake.
  • Historical Context (Oct 2025): Signed definitive agreement to acquire up to 40% equity in Canurta Inc., with second tranche expected by March 31, 2026.
Material Impact
  • Pipeline Progress: The approval for Phase 1 clinical trials is a necessary regulatory milestone that validates the preclinical mouse data and moves PD-001 from research to human testing. This confirms the strategic alignment with Canurta announced earlier in the year.
  • Valuation Impact: While positive, the news does not address the funding required to execute Phase 1 trials. Given the company's share price ($0.01) and existing debt obligations maturing October 2026, there is a high probability of future dilution or capital raising announcements which could offset positive sentiment.
  • Market Expectations: The acquisition of Canurta was announced in late 2025/early 2026 with the intent to advance cepharanthine development. This news confirms execution on that strategy but does not introduce a fundamentally new business model or revenue stream yet.
  • Risk Profile: The debt restructuring ($445,686) carries a conversion price of $0.05 against a current trading price of $0.01. If the stock remains depressed, holders may convert at maturity, causing significant dilution. Additionally, the second tranche of the Canurta acquisition was due by March 31, 2026; the May news does not explicitly confirm completion of this second tranche, creating uncertainty on full ownership integration.
  • Conclusion: The news is incremental progress within a high-risk capital structure environment. It supports the long-term thesis but does not resolve immediate solvency or dilution risks.
PHRX · Price
Company Overview
  • Company: PharmaDrug Inc. operates through subsidiaries including Sairiyo Therapeutics.
  • Flagship Project: PD-001 (Patented Reformulated Cepharanthine).
  • Indication: Currently exploring Hantavirus-related diseases (HFRS, hantavirus cardiopulmonary syndrome) following preclinical success. Previously associated with broader botanical drug development via Canurta partnership.
  • Development Stage: Phase 1 Clinical Study approved in Australia for safety and bioavailability. Preclinical data shows high inhibition rates in mouse models.
  • Strategy: Leveraging Canurta's IP portfolio to scale research using PharmaDrug's public market platform.
Read the original news release →

More from Pharmadrug Inc.

Jan 05, 2026 · 18:04

Pharmadrug closes acquisition of 19.9% in Canurta

Financings Jan 05, 2026 · 08:01

PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring

M&A / Property Oct 31, 2025 · 16:26

Pharmadrug arranges $445,686 debt restructuring

Financings Oct 30, 2025 · 18:29

Pharmadrug firms up deal to acquire 40% of Canurta

M&A / Property Oct 30, 2025 · 09:01

PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc

M&A / Property